Boehringer Ingelheim will make detailed clinical trial data available to the scientific community

Boehringer IngelheimIn order to add to scientific and medical progress, Boehringer Ingelheim is engaged in a program to make clinical study data and other clinical study related documents more widely accessible for approved products or after termination of a drug development program.

Clinical study reports and other clinical documents can be requested via the Boehringer Ingelheim website, accessible under http://trials.boehringer-ingelheim.com/trial_results.html. This website will also enable researchers to request access to de-identified patient level study data which form the basis of clinical trial findings.

Access to patient level data
Researchers will be granted access via a secure analysis environment after approval of his/her study proposal by an independent external review panel and based on a data sharing agreement. This agreement will include obligations such as the commitment to use the data only for the purpose of the study proposal, to not attempt to identify study participants, to not misuse the data, e. g. for own commercial interests, and to be "transparent" regarding the planned analysis and disclosure of results.

Documents and data to be shared will be redacted by Boehringer Ingelheim as far as this is necessary to protect on the one hand personal data of study participants, study personnel, and Boehringer Ingelheim employees and on the other side to protect Boehringer Ingelheim's commercial confidential information, in particular intellectual property rights.

Data and documents relating to studies initiated back until the year 1998 will be made available.

Publication of all scientific data
In addition, Boehringer Ingelheim confirmed its commitment to publish the scientific results from all sponsored studies in peer reviewed journals and at scientific meetings, regardless of study outcome for all types of clinical studies, Phase I - IV, interventional and non-interventional. Key Publications of Phase III clinical studies are being submitted to indexed, peer-reviewed journals no later than 12 to 18 months after completion of the clinical study.

These commitments were announced already in 2013 and are now being implemented with the website and the formation of a dedicated team to answer requests.

"The free exchange of scientific information is the basis for innovation in medicine. Boehringer Ingelheim as a research-driven pharmaceutical company is committed to the registration of all clinical studies prior to initiation and to disclosing all study results independent of outcome. Going beyond applicable regulatory and legal requirements, we at Boehringer Ingelheim feel it is the right approach and hope it will benefit science", said Dr Christopher Corsico, global Head of Clinical Development, Medicine and Regulatory at Boehringer Ingelheim.

Registration of all clinical studies
Going over and above regulatory and legal requirements, the company will register protocol information for all types of clinical studies on www.ClinicalTrials.gov, incl. Phase I studies in healthy volunteers as well as uncontrolled and non-interventional studies for all prescription and non-prescription drugs performed in any country world-wide. Boehringer Ingelheim commits to extend protocol registration to studies initiated 1998 or later. Starting with studies completing in 2014, the company will extend posting of study results on ClinicalTrials.gov also to products only approved outside the US and from terminated drug development programs.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

MSD Innovation Factory is looking for digital solu…

MSD is looking for innovators to solve 7 health-related challenges. One of them seeks to support anaesthesiologists with their continuous education (e.g. at the operation...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]